Ascentage Pharma Group Corp. Ltd. and Ascentage Pharma (Suzhou) Co. Ltd. have patented GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Chimeric antigen receptor (CAR) T-cell therapy is a powerful approach for patients with hematologic malignancies, such as leukemia. Its broad use may be associated with life-threatening toxicities such as neurotoxicity and cytokine release syndrome (CRS).
Secreting cytokines and killing tumor cells can be stressful for a T lymphocyte. In short adverse circumstances, these cells adapt to acute stress. If the situation persists, they activate a chronic stress response mechanism. According to a study by the Institute for Biomedical Research (IRB) in Barcelona, the cytoplasmic polyadenylation element-binding protein 4 (CPEB4) mediated this adaptation process.
Spark Biopharma Inc. has prepared and tested stimulator of interferon genes protein (STING; TMEM173) agonists that are reported to be useful for the treatment of cancer.
Mitogen-activated protein kinase kinase kinase 13 (MAP3K13; LZK) inhibitors reported to be useful for the treatment of cancer have been described in a recent U.S. Department of Health and Human Services patent.
Research at KHR Biotec GmbH has led to the development of eukaryotic initiation factor 4A (elF4A) and GTPase mutant inhibitors potentially useful for the treatment of cancer, craniofacial syndrome and neurofibromatosis type I.
Researchers from Shanxi Medical University and affiliated organizations presented data from a study that aimed to analyze the expression and prognostic value of mitochondrial-related genes in patients with stomach adenocarcinoma (STAD).
RSS
